The independent laboratory Invitro will conduct research on the effectiveness of the vaccine CoviShield/AstraZeneca, a press release of the company says.
Head of the laboratory’s clinical diagnostic complex Pavlo Naboka said that the study will consist in checking the amount of antibodies that were produced after vaccination.
“According to the official instructions, the principle of action of the CoviShield vaccine is based on the development of specific immunity to the S-protein (spike) of the SARS-CoV-2 coronavirus (the causative agent of COVID-19). The presence of a sufficient amount of antibodies to this protein is a factor that protects a person from the development of the disease even in case of infection. It is possible to check how many antibodies have developed in the body after vaccination by using a new laboratory test by the world famous manufacturer Abbott Diagnostics to quantify the level of neutralizing (protective) antibo
During the entire COVID-19 vaccination process, blood samples will be taken from laboratory staff to monitor immune levels, he said. That is, the laboratory will assess how many antibodies to SARS-CoV-2 will appear in a person after the first and second vaccinations, at what rate of antibodies will be produced, whether the actual concentration of antibodies will correspond to the data reported by the vaccine manufacturer.
According to the instructions, a sufficient level of antibodies should be formed within 90 days after the first administration of the vaccine. That is, the laboratory Invitro will be able to announce the results of the study in the summer of 2021.
An Oxford/AstraZeneca (Covishield) vaccine for emergency medical use against coronavirus (COVID-19) was registered in Ukraine on Monday, the Health Ministry’s press service said.
During a press briefing in Kyiv on Tuesday, Deputy Health Minister Yaroslav Kucher said the vaccine will arrive in Ukraine in the morning on Tuesday.
Previously, the Oxford/AstraZeneca vaccine for emergency use has already been approved by the World Health Organization (WHO), and the UK, EU and India have also given permission for its use.
Oxford/AstraZeneca (Covishield) applied for registration with the State Expert Center of the Health Ministry on February 15. Ukraine has a law that simplifies the registration procedure for COVID-19 vaccines and reduces it to five working days.
Oxford/AstraZeneca vaccine against coronavirus (COVID-19) has been submitted for registration in Ukraine under the obligation for emergency medical use.
According to the Center for Public Health website, an application for registration was submitted to the State Expert Center of the Health Ministry on Monday, February 15.
On the same day, WHO approved the AstraZeneca emergency vaccine and gave the green light for use of this vaccine worldwide through the COVAX initiative. The Oxford/AstraZeneca vaccine has previously been approved for emergency use in the UK, European Union and India.
The vaccine will be purchased for public funds directly from manufacturers. It is expected that at least 500,000 doses of the AstraZeneca vaccine will be supplied to Ukraine in February 2021.
As reported, Ukraine received information from COVAX on the supply of vaccines from the manufacturer Oxford/AstraZeneca in the amount of 2.2 to 3.7 million doses in the first or second quarter of 2021.
The vaccine produced by AstraZeneca may be delivered to Ukraine next week, Chief State Sanitary Doctor Viktor Liashko said.
“We are waiting for the Pfizer vaccine. Perhaps the first will be the AstraZeneca vaccine. We will receive two products next week. There are questions about the Pfizer vaccine, which we receive as part of the COVAX initiative, which is supplied to Ukraine for free,” Liashko said on the air of the Right to Power (Pravo na Vladu) program on 1+1 TV channel on Thursday night.
He noted that bureaucratic processes are currently underway.
Liashko said that vaccines would be used in Ukraine after their registration.
According to the Chief State Sanitary Doctor, Ukraine has agreed on a contract for the supply of 12 million doses of vaccines produced by AstraZeneca and Novavax. The drugs will be shipped from India, where they are manufactured at the facilities of the Serum Institute.
Also, through the COVAX mechanism, Ukraine should receive from 2.2 million to 3.7 million doses of the AstraZeneca vaccine in the first half of the year.
Vaccines against COVID-19 from four companies will arrive in Ukraine, President Volodymyr Zelensky has said.
“We have agreed to supply vaccines to Ukraine from Pfizer, Sinovac, AstraZeneca and Novavax companies. The first stage of vaccination will begin this month. Our doctors, the military and the National Guard will be the first to receive the vaccine,” Zelensky said at the opening of the “Ukraine 30. Coronavirus: Challenges and Responses” Forum on Monday.
At the same time, the president said that having already resolved the issue of vaccine supplies to the country, Ukraine faced a new problem, namely “lack of faith in vaccination, refusal to vaccinate by a significant part of the population.”
“This is a new but very serious issue that we all need to address. Personally I am ready, like most world leaders, to show that vaccination is important, safe and necessary,” the president said.
The president said that Ukraine will buy only safe vaccines from world manufacturers.
“There is no official information that the Russian vaccine has a 91% effect, neither from WHO nor from world experts. The head of WHO said today that there are several key points to pay attention to, one of them – fakes. Citizens of Ukraine are people and definitely not rabbits. We have no right to experiment on them,” Zelensky said.
“Today I will talk to Pfizer. We should get one million vaccines in February. In addition, there are agreements with the Chinese manufacturer. There are agreements with the U.K. and the United States,” he added.
The president said that Ukraine must purchase vaccines and provide an opportunity for all Ukrainians to be vaccinated. “As a state, we will lift the bans on people who are vaccinated or have contracted COVID-19,” Zelensky said.
The head of state also said that Ukraine has developed a vaccination roadmap, which provides for proper and equal access for all citizens of Ukraine.
“Its main task is to cover at least half of the population of Ukraine during 2021 and early 2022,” the president said.
Health Minister of Ukraine Maksym Stepanov told President Volodymyr Zelensky that today Ukraine received confirmation for the supply of 12 million doses of vaccines produced by AstraZeneca and Novavax, the presidential press service said.
“The sooner we receive vaccines, the faster we will overcome pandemics in Ukraine. I know that the Cabinet of Ministers is carefully working on the development of a website that will help Ukrainians to easily and conveniently register for vaccination. Like every Ukrainian, I look forward to the start of the vaccination process. Some 12 million doses is a good signal from our partners, and this will be enough to ensure vaccinations within the first months after the start of supplies,” Zelensky said.
Deliveries will take place from February 2021.
Thus, during a meeting with the president, Stepanov said an agreement had been reached on the supply of vaccines developed with the participation of AstraZeneca (Great Britain and Oxford University) and Novavax (the United States), which are produced under license agreements at the facilities of Serum Institute (India).
The confirmation received will be implemented through a contract between the Serum Institute and Crown Agents.